PHATHOM PHARMACEUTICALS, INC. Operating Expenses
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Operating Expenses of $63.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. operating expenses for the quarter ending 2026-06-30 was $63.14M, a 33.10% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. operating expenses for the quarter ending 2026-03-31 was $61.78M, a 40.40% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. operating expenses for the quarter ending 2025-12-31 was $55.86M, a 34.48% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. operating expenses for the quarter ending 2025-09-30 was $58.59M, a 30.91% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. operating expenses for fiscal 2025 was $312.50M, a 3.77% decline from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. operating expenses for fiscal 2024 was $324.75M, a 93.50% increase from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. operating expenses for fiscal 2023 was $167.83M, a 2.68% decline from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. operating expenses for fiscal 2022 was $172.44M, a 27.66% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $63.14M 10-Q · filed 2026-07-30 | $124.93M 10-Q · filed 2026-07-30 | $180.79M derived: sum of 3 quarters · filed 2026-07-30 | $239.37M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | $61.78M 10-Q · filed 2026-04-30 | $117.65M derived: sum of 2 quarters · filed 2026-04-30 | $176.23M derived: sum of 3 quarters · filed 2026-04-30 | $270.62M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | $55.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $114.45M derived: sum of 2 quarters · filed 2026-02-26 | $208.84M derived: sum of 3 quarters · filed 2026-07-30 | $312.50M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $58.59M 10-Q · filed 2025-10-30 | $152.97M derived: sum of 2 quarters · filed 2026-07-30 | $256.63M 10-Q · filed 2025-10-30 | $341.90M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | $94.39M 10-Q · filed 2026-07-30 | $198.05M 10-Q · filed 2026-07-30 | $283.31M derived: sum of 3 quarters · filed 2026-07-30 | $368.11M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | $103.66M 10-Q · filed 2026-04-30 | $188.92M derived: sum of 2 quarters · filed 2026-04-30 | $273.72M derived: sum of 3 quarters · filed 2026-04-30 | $356.96M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $85.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $170.06M derived: sum of 2 quarters · filed 2026-02-26 | $253.31M derived: sum of 3 quarters · filed 2026-02-26 | $324.75M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $84.79M 10-Q · filed 2025-10-30 | $168.04M derived: sum of 2 quarters · filed 2025-10-30 | $239.48M 10-Q · filed 2025-10-30 | $309.87M derived: sum of 4 quarters · filed 2025-10-30 | |
| 2024-06-30 | $83.25M 10-Q · filed 2025-08-07 | $154.69M 10-Q · filed 2025-08-07 | $225.08M derived: sum of 3 quarters · filed 2025-08-07 | $260.74M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $71.44M 10-Q · filed 2025-05-01 | $141.83M derived: sum of 2 quarters · filed 2025-05-01 | $177.49M derived: sum of 3 quarters · filed 2025-05-01 | $209.19M derived: sum of 4 quarters · filed 2025-05-01 | |
| 2023-12-31 | $70.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $106.05M derived: sum of 2 quarters · filed 2025-03-06 | $137.75M derived: sum of 3 quarters · filed 2025-03-06 | $167.83M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $35.66M 10-Q · filed 2024-11-07 | $67.36M derived: sum of 2 quarters · filed 2024-11-07 | $97.44M 10-Q · filed 2024-11-07 | $144.08M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $31.70M 10-Q · filed 2024-08-08 | $61.78M 10-Q · filed 2024-08-08 | $108.42M derived: sum of 3 quarters · filed 2024-08-08 | $150.95M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $30.08M 10-Q/A · filed 2024-06-14 | $76.72M derived: sum of 2 quarters · filed 2024-06-14 | $119.25M derived: sum of 3 quarters · filed 2024-06-14 | $164.61M derived: sum of 4 quarters · filed 2024-06-14 | |
| 2022-12-31 | $46.64M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | $89.17M derived: sum of 2 quarters · filed 2024-06-14 | $134.53M derived: sum of 3 quarters · filed 2024-06-14 | $172.44M 10-K/A · filed 2024-06-14 | |
| 2022-09-30 | $42.53M 10-Q · filed 2023-11-09 | $87.89M derived: sum of 2 quarters · filed 2023-11-09 | $125.80M 10-Q · filed 2023-11-09 | $158.84M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $45.36M 10-Q · filed 2023-08-10 | $83.27M 10-Q · filed 2023-08-10 | $83.27M 10-Q · filed 2022-08-02 | $116.31M derived: sum of 3 quarters · filed 2023-08-10 | $149.45M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $37.91M 10-Q · filed 2023-05-10 | $70.95M derived: sum of 2 quarters · filed 2023-05-10 | $104.08M derived: sum of 3 quarters · filed 2023-05-10 | $139.40M derived: sum of 4 quarters · filed 2023-05-10 | |
| 2021-12-31 | $33.04M derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-02-28 | $66.18M derived: sum of 2 quarters · filed 2023-02-28 | $101.50M derived: sum of 3 quarters · filed 2023-02-28 | $135.08M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $33.14M 10-Q/A · filed 2022-11-09 | $68.46M derived: sum of 2 quarters · filed 2022-11-09 | $102.04M 10-Q/A · filed 2022-11-09 | $154.48M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | $35.32M 10-Q · filed 2022-08-02 | $68.90M 10-Q · filed 2022-08-02 | $121.34M derived: sum of 3 quarters · filed 2022-08-02 | $154.17M derived: sum of 4 quarters · filed 2022-08-02 | |
| 2021-03-31 | $33.58M 10-Q · filed 2022-05-10 | $86.02M derived: sum of 2 quarters · filed 2022-05-10 | $118.85M derived: sum of 3 quarters · filed 2022-05-10 | $138.87M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | $52.44M 10-K · filed 2021-03-30 | $85.27M derived: sum of 2 quarters · filed 2021-11-08 | $105.29M derived: sum of 3 quarters · filed 2021-11-08 | $125.67M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $32.83M 10-Q · filed 2021-11-08 | $52.85M derived: sum of 2 quarters · filed 2021-11-08 | $73.23M 10-Q · filed 2021-11-08 | $88.92M derived: sum of 4 quarters · filed 2021-11-08 | |
| 2020-06-30 | $20.02M 10-Q · filed 2021-08-10 | $40.40M 10-Q · filed 2021-08-10 | $56.09M derived: sum of 3 quarters · filed 2021-08-10 | $62.37M derived: sum of 4 quarters · filed 2021-08-10 | |
| 2020-03-31 | $20.38M 10-Q · filed 2021-05-11 | $36.07M derived: sum of 2 quarters · filed 2021-05-11 | $42.35M derived: sum of 3 quarters · filed 2021-05-11 | $125.36M derived: sum of 4 quarters · filed 2021-05-11 | |
| 2019-12-31 | $15.69M 10-K · filed 2021-03-30 | $21.98M derived: sum of 2 quarters · filed 2021-03-30 | $104.99M derived: sum of 3 quarters · filed 2021-03-30 | $106.22M 10-K · filed 2021-03-30 | |
| 2019-09-30 | $6.28M 10-K · filed 2021-03-30 | $89.30M derived: sum of 2 quarters · filed 2021-03-30 | $90.52M 10-Q · filed 2020-11-10 | $90.97M derived: sum of 4 quarters · filed 2021-03-30 | |
| 2019-06-30 | $83.01M 10-K · filed 2021-03-30 | $84.24M 10-Q · filed 2020-08-06 | $84.69M derived: sum of 3 quarters · filed 2021-03-30 | $84.96M derived: sum of 4 quarters · filed 2021-03-30 | |
| 2019-03-31 | $1.23M 10-K · filed 2021-03-30 | $1.68M derived: sum of 2 quarters · filed 2021-03-30 | $1.95M derived: sum of 3 quarters · filed 2021-03-30 | $2.20M derived: sum of 4 quarters · filed 2021-03-30 | |
| 2018-12-31 | $451.00K 10-K · filed 2020-03-19 | $719.00K derived: sum of 2 quarters · filed 2020-03-19 | $974.00K derived: sum of 3 quarters · filed 2020-03-19 | $1.23M 10-K · filed 2020-03-19 | |
| 2018-09-30 | $268.00K 10-K · filed 2020-03-19 | $523.00K derived: sum of 2 quarters · filed 2020-03-19 | $774.00K 10-Q · filed 2019-11-25 | ||
| 2018-06-30 | $255.00K 10-K · filed 2020-03-19 | $506.00K derived: sum of 2 quarters · filed 2020-03-19 | |||
| 2018-03-31 | $251.00K 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |